01.07.2014 | Erratum
Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2014
Einloggen, um Zugang zu erhalten